{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T08:30:00Z","timestamp":1724488200523},"reference-count":51,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1248\/bpb.b19-00201","type":"journal-article","created":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T18:03:25Z","timestamp":1561917805000},"page":"1064-1068","source":"Crossref","is-referenced-by-count":3,"title":["Effects of Distigmine on the Mechanical Activity of Urinary Bladder Smooth Muscle"],"prefix":"10.1248","volume":"42","author":[{"given":"Keisuke","family":"Obara","sequence":"first","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Schmid O. US Patent 2789981 (1957)."},{"key":"2","unstructured":"2) Pateisky K. Treatment of myasthenia gravis pseudoparalytica; clinical testing and therapy with BC substances (BC40, BC47, BC48 and BC 51). <i>Wien. Z. Nervenheilkd. Grenzgeb.<\/i>, <b>17<\/b>, 53\u201384 (1959)."},{"key":"3","unstructured":"3) Emeryk E, Wasowicz B. Evaluation of \u201cUbretid\u201d (BC 51) in the treatment of myasthenia gravis. <i>Neurol. Neurochir. Psychiatr. Pol.<\/i>, <b>13<\/b>, 611\u2013617 (1963)."},{"key":"4","unstructured":"4) Ishigaki K, Murakami T, Ito Y, Yanagisawa A, Kodaira K, Shishikura K, Suzuki H, Hirayama Y, Osawa M. Treatment approach to congenital myasthenic syndrome in a patient with acetylcholine receptor deficiency. <i>No To Hattatsu<\/i>, <b>41<\/b>, 37\u201342 (2009)."},{"key":"5","unstructured":"5) Antimyasthenics. <i>Martindale: the complete drug reference<\/i>, 39th ed. (Brayfield A ed.) Pharmaceutical Press, London, pp. 694\u2013700 (2017)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ishikawa S, Tsukahara S, Sato Y. Local administration of 1% Ubretid in the handling of glaucoma, myasthenia gravis and esotropia. <i>Ophthalmologica<\/i>, <b>159<\/b>, 339\u2013362 (1969).","DOI":"10.1159\/000305931"},{"key":"7","unstructured":"7) Mizukawa T, Azuma I. Effects of Ubretid eye-drops upon glaucoma. <i>Nihon Ganka Kiyo<\/i>, <b>21<\/b>, 586\u2013595 (1970)."},{"key":"8","unstructured":"8) Sawada A, Hara K, Futa R, Ogata H. Pressure-lowering effect of a new cholinesterase inhibitor, Ubretid, on glaucoma. <i>Nihon Ganka Kiyo<\/i>, <b>22<\/b>, 676\u2013682 (1971)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Cameron MD. Distigmine bromide (Ubretid) in the prevention of postoperative retention of urine. <i>J. Obstet. Gynaecol. Br. Commonw.<\/i>, <b>73<\/b>, 847\u2013848 (1966).","DOI":"10.1111\/j.1471-0528.1966.tb06096.x"},{"key":"10","unstructured":"10) Oka N, Hasegawa S. Treatment of dysuria with anticholinesterases: Ubretid. <i>Hinyokika Kiyo<\/i>, <b>13<\/b>, 42\u201351 (1967)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yeo J, Southwell P, Hindmarsh E. Preliminary report on the effect of distigmine bromide on the neurogenic bladder. <i>Med. J. Aust.<\/i>, <b>1<\/b>, 116\u2013120 (1973).","DOI":"10.5694\/j.1326-5377.1973.tb119654.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Smith PH, Cook JB, Prasad EW. The effect of Ubretid on bladder function after recent complete spinal cord injury. <i>Br. J. Urol.<\/i>, <b>46<\/b>, 187\u2013192 (1974).","DOI":"10.1111\/j.1464-410X.1974.tb03742.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Yeo J, Southwell P, Rutowski S, Marchant-Williams H. A further report on the effect of distigmine bromide (Ubretid) on the neurogenic bladder. <i>Med. J. Aust.<\/i>, <b>2<\/b>, 201\u2013203 (1974).","DOI":"10.5694\/j.1326-5377.1974.tb70704.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Philp NH, Thomas DG. The effect of distigmine bromide on voiding in male paraplegic patients with reflex micturition. <i>Br. J. Urol.<\/i>, <b>52<\/b>, 492\u2013496 (1980).","DOI":"10.1111\/j.1464-410X.1980.tb03098.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tanaka Y, Masumori N, Itoh N, Furuya S, Nishizawa O, Tsukamoto T. Symptomatic and urodynamic improvement by oral distigmine bromide in poor voiders after transurethral resection of the prostate. <i>Urology<\/i>, <b>57<\/b>, 270\u2013274 (2001).","DOI":"10.1016\/S0090-4295(00)00924-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Bougas DA, Mitsogiannis IC, Mitropoulos DN, Kollaitis GC, Serafetinides EN, Giannopoulos AM. Clinical efficacy of distigmine bromide in the treatment of patients with underactive detrusor. <i>Int. Urol. Nephrol.<\/i>, <b>36<\/b>, 507\u2013512 (2004).","DOI":"10.1007\/s11255-004-0847-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Yamanishi T, Yasuda K, Kamai T, Tsujii T, Sakakibara R, Uchiyama T, Yoshida K. Combination of a cholinergic drug and an \u03b1-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. <i>Int. J. Urol.<\/i>, <b>11<\/b>, 88\u201396 (2004).","DOI":"10.1111\/j.1442-2042.2004.00753.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Tanaka Y, Masumori N, Tsukamoto T, Furuya S, Furuya R, Ogura H. Treatment strategy according to findings on pressure-flow study for women with decreased urinary flow rate. <i>Adv. Urol.<\/i>, <b>2009<\/b>, 782985 (2009).","DOI":"10.1155\/2009\/782985"},{"key":"19","unstructured":"19) Skolarikos A, Tyritzis S, Stamatiou K. Cholinergic drugs for treatment of recurrent urinary retention in high surgical risk\/elderly BPH patients. A pilot study. <i>Minerva Urol. Nefrol.<\/i>, <b>64<\/b>, 209\u2013216 (2012)."},{"key":"20","unstructured":"20) Izumi K, Maolake A, Maeda Y, Shigehara K, Namiki M. Effects of bethanechol chloride and distigmine bromide on postvoiding residual volume in patients with underactive bladder. <i>Minerva Urol. Nefrol.<\/i>, <b>66<\/b>, 241\u2013247 (2014)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Sugaya K, Kadekawa K, Onaga T, Ashitomi K, Mukouyama H, Nakasone K, Shimabukuro H, Shimabukuro S, Matayoshi Y, Hokama S, Touyama Y, Nishijima S. Effect of distigmine at 5\u2009mg daily in patients with detrusor underactivity. <i>Nippon Hinyokika Gakkai Zasshi<\/i>, <b>105<\/b>, 10\u201316 (2014).","DOI":"10.5980\/jpnjurol.105.10"},{"key":"22","unstructured":"22) Eto R, Naganuma H, Fuji I. Antidepressant induced urinary retention. <i>Ky\u016bsh\u016b Seishin Shinkei Igaku<\/i>. <i>Kyushu Neuropsych.<\/i>, <b>34<\/b>, 308\u2013311 (1988)."},{"key":"23","unstructured":"23) Tsuno N, Miyata H, Nakayama K. Dysuria induced by psychotropic drugs\u2014appropriate usage of distigmine bromide (Ubretid), therapeutic medicine of dysuria. <i>No to Seishin no Igaku<\/i>. <i>Brain Sci. Ment. Disord.<\/i>, <b>14<\/b>, 149\u2013153 (2003)."},{"key":"24","unstructured":"24) Katsumi T, Murayama K. Clinical effects of distigmine bromide (Ubretid), a cholinesterase inhibitor, on micturition disturbance by benign prostatic hypertrophy\u2014comparative study of distigmine bromide and the combination of distigmine bromide and adrenergic blocker. <i>Hinyokika Kiyo<\/i>, <b>38<\/b>, 1089\u20131092 (1992)."},{"key":"25","unstructured":"25) Shibayama K, Makino T, Machida M, Hatori M. Combination therapy using Ubretid and prostal for micturition disturbance due to benign prostatic hypertrophy. <i>Jpn. Pharmacol. Ther.<\/i>, <b>20<\/b>, 3839\u20133843 (1992)."},{"key":"26","unstructured":"26) Mikami Y, Araki I, Maezawa H, Takeda M. Efficacy of the combination therapy with alpha1-adrenergic blocker and distigmine bromide in micturition difficulty suggesting benign prostatic hyperplasia. <i>Jpn. J. Urol. Surg.<\/i>, <b>20<\/b>, 1207\u20131213 (2007)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Matsuya H, Sekido N, Kida J, Mashimo H, Wakamatsu D, Okada H. Effects of an EP2 and EP3 receptor dual agonist, ONO-8055, on a radical hysterectomy-induced underactive bladder model in monkeys. <i>Low. Urin. Tract Symptoms<\/i>, <b>10<\/b>, 204\u2013211 (2018).","DOI":"10.1111\/luts.12166"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Tatemichi S, Tsuchioka K, Yonekubo S, Maruyama K, Kobayashi M. Effects of silodosin, an \u03b1<sub>1A<\/sub>-adrenoceptor antagonist, and distigmine, an acetylcholinesterase inhibitor, and their combined effects on impaired voiding function in Zucker diabetic fatty rats. <i>Pharmacology<\/i>, <b>95<\/b>, 285\u2013292 (2015).","DOI":"10.1159\/000398811"},{"key":"29","unstructured":"29) Obara K, Chino D, Tanaka Y. The recovery effects of distigmine on guinea pig detrusor underactivity induced by anticholinergic drugs. <i>\u014cy\u014d Yakuri\/Pharmacometrics<\/i>, <b>91<\/b>, 25\u201339 (2016)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ambache N, Zar MA. Non-cholinergic transmission by post-ganglionic motor neurones in the mammalian bladder. <i>J. Physiol.<\/i>, <b>210<\/b>, 761\u2013783 (1970).","DOI":"10.1113\/jphysiol.1970.sp009240"},{"key":"31","unstructured":"31) Burnstock G, Dumsday B, Smythe A. Atropine resistant excitation of the urinary bladder: the possibility of transmission <i>via<\/i> nerves releasing a purine nucleotide. <i>Br. J. Pharmacol.<\/i>, <b>44<\/b>, 451\u2013461 (1972)."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Westfall DP, Fedan JS, Colby J, Hogaboom GK, O\u2019Donnell JP. Evidence for a contribution by purines to the neurogenic response of the guinea-pig urinary bladder. <i>Eur. J. Pharmacol.<\/i>, <b>87<\/b>, 415\u2013422 (1983).","DOI":"10.1016\/0014-2999(83)90080-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Moss HE, Burnstock G. A comparative study of electrical field stimulation of the guinea-pig, ferret and marmoset urinary bladder. <i>Eur. J. Pharmacol.<\/i>, <b>114<\/b>, 311\u2013316 (1985).","DOI":"10.1016\/0014-2999(85)90375-9"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Brading AF, Mostwin JL. Electrical and mechanical responses of guinea-pig bladder muscle to nerve stimulation. <i>Br. J. Pharmacol.<\/i>, <b>98<\/b>, 1083\u20131090 (1989).","DOI":"10.1111\/j.1476-5381.1989.tb12651.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kura H, Obara K, Yabu H. Contractile responses to electrical field stimulation and ATP in guinea-pig urinary bladder. <i>Comp. Biochem. Physiol. C.<\/i>, <b>102<\/b>, 193\u2013197 (1992).","DOI":"10.1016\/0742-8413(92)90063-D"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Shinkai M, Takayanagi I, Kato T. Tachykinin receptors of the NK<sub>2<\/sub> type involved in the acetylcholine release by nicotine in guinea-pig bladder. <i>Br. J. Pharmacol.<\/i>, <b>108<\/b>, 759\u2013762 (1993).","DOI":"10.1111\/j.1476-5381.1993.tb12874.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Ito Y, Harada T, Fushimi K, Kagawa Y, Oka H, Nakazawa H, Homma R, Kato Y, Yamada S. Pharmacokinetic and pharmacodynamic analysis of acetylcholinesterase inhibition by distigmine bromide in rats. <i>Drug Metab. Pharmacokinet.<\/i>, <b>25<\/b>, 254\u2013261 (2010).","DOI":"10.2133\/dmpk.25.254"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Obara K, Chino D, Tanaka Y. Distigmine bromide produces sustained potentiation of guinea-Pig urinary bladder motility by inhibiting cholinesterase activity. <i>Biol. Pharm. Bull.<\/i>, <b>40<\/b>, 807\u2013814 (2017).","DOI":"10.1248\/bpb.b16-00901"},{"key":"39","unstructured":"39) Horinouchi T, Aoki T, Akiyama R, Ono T, Shibano M, Tanaka Y, Koike K. Effects of distigmine, a long-acting cholinesterase inhibitor, on urinary bladder detrusor and urethra smooth muscles of guinea-pig: pharmacological analysis <i>in vitro<\/i> and <i>in vivo. \u014cy\u014d Yakuri\/Pharmacometrics<\/i>, <b>64<\/b>, 45\u201352 (2003)."},{"key":"40","unstructured":"40) Sekiya S, Takahashi H, Seki Y, Teraoka A, Aikawa N, Tanaka Y, Koike K. Comparison of the effects of distigmine and neostigmine on guinea-pig urinary bladder contractile functions assessed by <i>in vivo<\/i> and <i>in vitro<\/i> studies. <i>\u014cy\u014d Yakuri\/Pharmacometrics<\/i>, <b>75<\/b>, 85\u201396 (2008)."},{"key":"41","unstructured":"41) Obara K, Aikawa N, Sato K, Chino D, Tanaka Y. Comparison of the effects of distigmine and bethanechol on guinea-pig lower urinary tracts contractile functions assessed by <i>in vivo<\/i> and <i>in vitro<\/i> studies. <i>\u014cy\u014d Yakuri\/Pharmacometrics<\/i>, <b>85<\/b>, 101\u2013114 (2013)."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Obara K, Ogawa T, Chino D, Tanaka Y. The long-lasting enhancing effect of distigmine on acetylcholine-induced contraction of guinea pig detrusor smooth muscle correlates with its anticholinesterase activity. <i>Biol. Pharm. Bull.<\/i>, <b>40<\/b>, 1092\u20131100 (2017).","DOI":"10.1248\/bpb.b17-00175"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Kullmann FA, Kurihara R, Ye L, Wells GI, McKenna DG, Burgard EC, Thor KB. Effects of the 5-HT<sub>4<\/sub> receptor agonist, cisapride, on neuronally evoked responses in human bladder, urethra, and ileum. <i>Auton. Neurosci.<\/i>, <b>176<\/b>, 70\u201377 (2013).","DOI":"10.1016\/j.autneu.2013.02.020"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Obara K, Kobayashi Y, Chino D, Tanaka Y. Effect of distigmine on the contractile response of guinea pig urinary bladder to electrical field stimulation. <i>Eur. J. Pharmacol.<\/i>, <b>809<\/b>, 209\u2013214 (2017).","DOI":"10.1016\/j.ejphar.2017.05.031"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Obara K, Kobayashi Y, Chino D, Tanaka Y. Effects of distigmine on electrical field stimulation-induced contraction of mouse urinary bladder smooth muscles. <i>Pharmacology<\/i>, <b>99<\/b>, 106\u2013113 (2017).","DOI":"10.1159\/000452222"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Nagabukuro H, Doi T. Differential effects of TAK-802, a selective acetylcholinesterase inhibitor, and carbamate acetylcholinesterase inhibitors on contraction of the detrusor smooth muscle of the guinea pig. <i>Life Sci.<\/i>, <b>77<\/b>, 3276\u20133286 (2005).","DOI":"10.1016\/j.lfs.2005.04.028"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Harada T, Fushimi K, Kato A, Ito Y, Nishijima S, Sugaya K, Yamada S. Demonstration of muscarinic and nicotinic receptor binding activities of distigmine to treat detrusor underactivity. <i>Biol. Pharm. Bull.<\/i>, <b>33<\/b>, 653\u2013658 (2010).","DOI":"10.1248\/bpb.33.653"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Yoshida M, Inadome A, Maeda Y, Satoji Y, Masunaga K, Sugiyama Y, Murakami S. Non-neuronal cholinergic system in human bladder urothelium. <i>Urology<\/i>, <b>67<\/b>, 425\u2013430 (2006).","DOI":"10.1016\/j.urology.2005.08.014"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Frazier EP, Peters SL, Braverman AS, Ruggieri MR Sr, Michel MC. Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors. <i>Naunyn Schmiedebergs Arch. Pharmacol.<\/i>, <b>377<\/b>, 449\u2013462 (2008).","DOI":"10.1007\/s00210-007-0208-0"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Griffin CS, Bradley E, Dudem S, Hollywood MA, McHale NG, Thornbury KD, Sergeant GP. Muscarinic receptor induced contractions of the detrusor are mediated by activation of TRPC4 channels. <i>J. Urol.<\/i>, <b>196<\/b>, 1796\u20131808 (2016).","DOI":"10.1016\/j.juro.2016.05.108"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Kennedy C. ATP as a cotransmitter in the autonomic nervous system. <i>Auton. Neurosci.<\/i>, <b>191<\/b>, 2\u201315 (2015).","DOI":"10.1016\/j.autneu.2015.04.004"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/7\/42_b19-00201\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T12:46:24Z","timestamp":1575204384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/7\/42_b19-00201\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b19-00201","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}